Big Pharma War and FDA on Anticancer Drug Discoverer and Producer of Antineoplaston/ 2021-05-17. Jorma Jyrkkanen

Dr Burzynski discovered that phenylacetate and phenylacetylamine were successful in treating a number of cancers. The Government wanted to steal his discovery and patent it for their own use. This is what the years of harrassment were all about. Clinical Trial Drugs R D . 2003;4(2):91-101. doi: 10.2165/00126839-200304020-00002. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report Stanislaw R Burzynski 1 , Robert I Lewy, Robert A Weaver, Maxwell L Axler, Tomasz J Janicki, Gabor F Jurida, Jaroslaw K Paszkowiak, Barbara G Szymkowski, Mohammad I Khan, Mark Bestak Affiliations PMID: 12718563 DOI: 10.2165/00126839-200304020-00002 Abstract Objective: A phase II study of antineoplaston A10 and AS2-1 was conducted to evaluate the antineoplastic activity in patients with recurrent diffuse intrinsic brain stem glioma. Patients and methods: This report describes the results of treatment of the first 12 patients admitted to the study. Patients received escalating doses of antineoplaston A10 and AS2-1 by intravenous bolus injections. The median duration of treatment was 6 months and the average dosage of antineoplaston A10 was 11.3 g/kg/day and of antineoplaston AS2-1 0.4 g/kg/day. Responses were assessed by gadolinium-enhanced magnetic resonance imaging of the head. Results: Of ten evaluable patients, complete response was determined in two cases (20%), partial response in three (30%), stable disease in three (30%) and progressive disease in two (20%). Survival at 2 years was 33.3%. Currently, of all 12 patients, two (17%) were alive and tumour free for over 5 years since initial diagnosis; one was alive for more than 5 years, and another for more than 4 years from the start of treatment. Only mild and moderate toxicities were observed, which included three cases of skin allergy, two cases of anaemia, fever and hypernatraemia, and single cases of agranulocytosis, hypoglycaemia, numbness, tiredness, myalgia and vomiting. Conclusion: The results of this study compared favourably with the responses of patients treated with radiation therapy and chemotherapy. The study continues with accrual of additional patients. Similar articles Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M. Drugs R D. 2004;5(6):315-26. doi: 10.2165/00126839-200405060-00002. PMID: 15563234 Clinical Trial. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. Childs Nerv Syst. 2014 Dec;30(12):2051-61. doi: 10.1007/s00381-014-2401-z. Epub 2014 Apr 10. PMID: 24718705 Free PMC article. Clinical Trial. Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al. Massimino M, Clerici CA. Childs Nerv Syst. 2014 Dec;30(12):2065-6. doi: 10.1007/s00381-014-2511-7. Epub 2014 Jul 31. PMID: 25079885 Clinical Trial. No abstract available. The present state of antineoplaston research (1). Burzynski SR. Integr Cancer Ther. 2004 Mar;3(1):47-58. doi: 10.1177/1534735403261964. PMID: 15035876 Review. Potential of antineoplastons in diseases of old age. Burzynski SR. Drugs Aging. 1995 Sep;7(3):157-67. doi: 10.2165/00002512-199507030-00001. PMID: 8535046 Review. No abstract available. Video Documentary Exposing the Crimes of Govt and Medicine for Profit. https://documentaryheaven.com/burzynski-cancer-cure-cover-up/